Cantor Fitzgerald raises target for Pfizer stock to USD 28.00

Published on 10/08/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor Fitzgerald set a USD 28.00 target after USD 27.00. Pfizer stock was EUR 24.71 on October 8, 2026, down 1.12 percent from EUR 24.99.

Key points in brief

Das Wichtigste in Kürze

Cantor Fitzgerald raised its Pfizer stock target from USD 27.00 to USD 28.00 on October 8, 2026, while keeping a Neutral rating.
Pfizer reported USD 15.03 billion in second-quarter revenue and adjusted diluted earnings per share of USD 0.77.
The Lang & Schwarz price was EUR 24.71 on October 8, 2026, down 1.12 percent from the EUR 24.99 prior close.

Fotorealistische unbeschriftete Pharma-Anlage bei Dämmerung, Symbolbild für Pfizer Inc — Fotorealistische Pharma-Produktionsanlage bei Dämmerung symbolisiert Pfizer Inc. mit ISIN US7170811035 im Biotech-Sektor, Illustration mit AI erstellt.

Pfizer stock (ISIN US7170811035) was EUR 24.71 at Lang & Schwarz on October 8, 2026, at 4:09 p.m. CEST, down 1.12 percent from the EUR 24.99 prior close. According to Investing.com on October 8, 2026, Cantor Fitzgerald raised its Pfizer target from USD 27.00 to USD 28.00 and kept a Neutral rating.

Pfizer built momentum in the second quarter

Pfizer's second-quarter 2026 revenue reached USD 15.03 billion, according to the Yahoo Finance transcript dated August 4, 2026. Adjusted diluted earnings per share was USD 0.77, while reported earnings per share was minus USD 0.04 after a USD 4.30 billion non-cash intangible asset impairment.

The same transcript said launched and acquired products generated USD 3.20 billion in second-quarter revenue and grew 18.00 percent operationally. Excluding one-time items recorded in the second quarter of 2025, that growth rate was 27.00 percent, giving investors a clearer view of the businesses Pfizer is using to offset weaker COVID-related demand.

Three dated milestones shape the story

On August 4, 2026, Pfizer reported second-quarter revenue of USD 15.03 billion and adjusted diluted earnings per share of USD 0.77, according to Yahoo Finance. On September 22, 2026, Pfizer announced a fourth-quarter cash dividend of USD 0.43 per common share, according to Business Wire. On October 8, 2026, Cantor Fitzgerald lifted its target from USD 27.00 to USD 28.00 while retaining Neutral, according to MarketBeat.

What does the target increase mean?

The USD 28.00 target is USD 3.29 above the Lang & Schwarz euro price only in nominal terms and therefore does not support a cross-currency upside calculation. The more useful comparison is within Pfizer's own reporting: second-quarter revenue of USD 15.03 billion exceeded the USD 14.42 billion estimate cited by Investing.com, while adjusted diluted earnings per share of USD 0.77 exceeded the USD 0.68 estimate. Cantor Fitzgerald also pointed to dependence on the MEVPRO-1 readout and continuing questions about longer-term growth and dividend sustainability.

Next dates are already scheduled

Pfizer's next reporting date is November 3, 2026, when it plans to issue its third-quarter 2026 performance report and hold an analyst conference call, according to Business Wire. The dividend record date is November 6, 2026, and payment is scheduled for December 7, 2026.

Pfizer stock stays below its yearly high

Pfizer stock was trading at EUR 24.71 at Lang & Schwarz on October 8, 2026, at 4:09 p.m. CEST, down 1.12 percent versus the EUR 24.99 prior close dated October 7, 2026. On the NYSE, the stock was last at USD 27.65 on October 8, 2026, at 10:21 a.m. EDT; its 52-week range was USD 23.62 to USD 29.21 and market capitalization was USD 157.6 billion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.